Skip to main content

Seneca provides further support to Optibiotix

Seneca provides further support to Optibiotix

A York life sciences business developing products to tackle obesity, high cholesterol and diabetes has raised £1m of funding in a placing which has led to Seneca Partners increasing its stake.

Stephen O’Hara, chief executive of OptiBiotix, said: “We are delighted that Seneca, as a major shareholder and respected wealth manager, have increased their stake in OptiBiotix. The funds will be used to further accelerate our development programmes to capitalise on the growing number of opportunities arising in the rapidly evolving microbiome space and build shareholder value.”

See the article in full at InsiderMedia.com